---
title: "AGS released its 2024 annual performance, with a net profit attributable to the parent company of 293 million yuan, a year-on-year increase of 35.06%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236984345.md"
description: "AGS released its 2024 annual performance, with operating revenue of 637 million yuan, a year-on-year increase of 25.14%; net profit attributable to the parent company of 293 million yuan, a year-on-year increase of 35.06%; net profit excluding non-recurring gains and losses of 273 million yuan, a year-on-year increase of 28.62%; basic earnings per share of 3.64 yuan/share. The company plans to distribute a cash dividend of 13.8 yuan (including tax) for every 10 shares"
datetime: "2025-04-22T13:04:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236984345.md)
  - [en](https://longbridge.com/en/news/236984345.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236984345.md)
---

# AGS released its 2024 annual performance, with a net profit attributable to the parent company of 293 million yuan, a year-on-year increase of 35.06%

According to the Zhitong Finance APP, AGS (688581.SH) released its annual report for 2024, with an operating income of 637 million yuan for the year, a year-on-year increase of 25.14%; net profit attributable to shareholders of the listed company was 293 million yuan, a year-on-year increase of 35.06%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 273 million yuan, a year-on-year increase of 28.62%; basic earnings per share were 3.64 yuan/share. It is proposed to distribute a cash dividend of 13.8 yuan (including tax) for every 10 shares

### Related Stocks

- [688581.CN](https://longbridge.com/en/quote/688581.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Russia plans to return staff to Iranian Bushehr nuclear plant in coming weeks, RIA reports](https://longbridge.com/en/news/286905394.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [Allen & Heath Rolls Out New SQ+ Lineup of Digital Mixers Announced; First Look YouTube Video on SQ5+,   SQ6+, and   SQ7+ Digital Mixers at B&H](https://longbridge.com/en/news/287101198.md)